Article - Limited access to UNIGE
Other version: http://onlinelibrary.wiley.com/store/10.1111/j.1365-2133.2005.06423.x/asset/j.1365-2133.2005.06423.x.pdf?v=1&t=hkp79z...
Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases
|Published in||British Journal of Dermatology. 2005, vol. 152, no. 5, p. 1048-1050|
|Abstract||Alefacept is a fully human fusion protein for use in adult patients with moderate to severe chronic plaque psoriasis. Its dual mechanism of action involves inhibition of T-cell activation and selective reduction of memory T cells. We report the clinical course of two patients with hepatitis C virus (HCV) infection who have received alefacept for psoriasis. Consistent with its mechanism of action, administration of alefacept led to transient decreases in CD4+ and CD8+ T-cell counts. However, these reductions were not associated with an increase in HCV viral load or exacerbation of infection. Liver enzymes remained stable throughout the treatment and follow-up periods. Alefacept has a selective mechanism of action that specifically targets memory T cells and this selectivity may account for its safety and tolerability in patients with hepatitis.|
|Keywords||Adult — CD4 Lymphocyte Count — CD8-Positive T-Lymphocytes/immunology — Hepatitis C/*complications/immunology/virology — Humans — Immunosuppressive Agents/*therapeutic use — Lymphocyte Count — Male — Middle Aged — Psoriasis/complications/*drug therapy/immunology — Recombinant Fusion Proteins/*therapeutic use — Viral Load|
|THACI, Diamant et al. Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases. In: British Journal of Dermatology, 2005, vol. 152, n° 5, p. 1048-1050. https://archive-ouverte.unige.ch/unige:29842|